Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping – scoping review
Annales Pharmaceutiques Françaises · 2026-11 · 84 (6) · 988-997
DOI: 10.1016/j.pharma.2026.06.008 ↗Kurz gefasst
Scoping Review in der Zeitschrift Annales Pharmaceutiques Françaises, 2026-11. Verfasst von João Pedro Henriques und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de médecine de Bauru, université de São Paulo (FMBRU-USP), Alameda Dr. Octávio Pinheiro Brisolla, 9-75, Bauru, SP, 17012-901, Brazil. Electro…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Anti-Inflammatory Agents, Periodontium, Periodontal Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Diabetes mellitus and periodontal disease are highly prevalent chronic disorders linked by bidirectional inflammatory and oxidative pathways. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging pharmacologic agents with anti-inflammatory properties that may benefit periodontal tissues, although the available evidence remains limited. This scoping review aimed to map the available evidence on the effects of GLP-1 RA on periodontal tissues and their underlying mechanisms of action. METHODS: Following the Joanna Briggs Institute methodology and the PRISMA-ScR extension, a systematic search was conducted across PubMed/MEDLINE, Web of Science, Scopus, Embase, LILACS, and the Cochrane Library for studies evaluating the impact of GLP-1 RA in periodontal models or tissues, without date restriction. Records were screened against predefined eligibility criteria, and data were charted using a structured extraction form. RESULTS: Seven studies, published between 2015 and 2022, met the inclusion criteria: three animal studies, three in vitro studies, and one mixed-design study; no clinical trial was identified. Liraglutide was the most studied agent (four out of seven studies). GLP-1 RA were associated with reduced pro-inflammatory signalling, attenuated alveolar bone resorption, and enhanced osteogenic differentiation, frequently through NF-κB/MAPK and Wnt/β-catenin pathways. One study showed reduced inflammatory markers without reduced bone loss. CONCLUSION: Current evidence is exclusively preclinical, conducted predominantly with liraglutide, and insufficient to support any therapeutic indication. These findings identify a biologically plausible hypothesis that warrants strict future clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculté de médecine de Bauru, université de São Paulo (FMBRU-USP), Alameda Dr. Octávio Pinheiro Brisolla, 9-75, Bauru, SP, 17012-901, Brazil. Electronic address: jpedrohenriques12@usp.br.
- Faculté d'odontologie de Bauru, université de São Paulo (FOB-USP), Bauru, SP, Brazil.
- Faculté de médecine de Bauru, université de São Paulo (FMBRU-USP), Alameda Dr. Octávio Pinheiro Brisolla, 9-75, Bauru, SP, 17012-901, Brazil.
Zitieren
APA
Henriques, J. P., Weckwerth, A. V. B., Santana, A. C. P., Damante, C. A., Santos, C. F. D., & Negrato, C. A. (2026). Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping – scoping review. Annales Pharmaceutiques Françaises, 84(6), 988-997. https://doi.org/10.1016/j.pharma.2026.06.008
Vancouver
Henriques JP, Weckwerth AVB, Santana ACP, Damante CA, Santos CFD, Negrato CA. Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping – scoping review. Annales Pharmaceutiques Françaises. 2026;84(6):988-997. doi:10.1016/j.pharma.2026.06.008
BibTeX
@article{Henriques2026,
author = {Henriques, João Pedro and Weckwerth, Artur Villas Boas and Santana, Adriana Campos Passanezi and Damante, Carla Andreoti and Santos, Carlos Ferreira Dos and Negrato, Carlos Antonio},
title = {Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping – scoping review},
journal = {Annales Pharmaceutiques Françaises},
year = {2026},
volume = {84},
number = {6},
pages = {988--997},
doi = {10.1016/j.pharma.2026.06.008}
}
EUVIMED